Cross-talk and modulation of signaling between somatostatin and growth factor receptors

Endocrine

Volumn 40, Issue 2, 2011, Pages 168-180

  Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dimerization; G protein coupled receptors; Receptor tyrosine kinase; Signaling; Somatostatin receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

CELL SURFACE; CELLULAR DISTRIBUTION; DIMERIZATION; HUMAN; INTERNALIZATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

EID: 84855195867     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9524-8     Document Type: Review

References (102)

1. D. Fotiadis, Y. Liang, S. Filipek, D.A. Saperstein, A. Engel, K. Palczewski, Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421(6919), 127-128 (2003) (Pubitemid 36090969)
2. M. Bouvier, N. Heveker, R. Jockers, S. Marullo, G. Milligan, BRET analysis of GPCR oligomerization: newer does not mean better. Nat. Methods 4(1), 3-4 (2007). author reply 4 3. (Pubitemid 46029461)
3. G. Milligan, G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66(1), 1-7 (2004) (Pubitemid 38822080)
4. U. Kumar, M. Grant, Somatostatin and somatostatin receptors. Results Probl. Cell Differ. 50, 137-184 (2010)
5. Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001) (Pubitemid 33674041)
6. J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell 103(2), 211-225 (2000)
7. H. Daub, C. Wallasch, A. Lankenau, A. Herrlich, A. Ullrich, Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 16(23), 7032-7044 (1997) (Pubitemid 27520803)
8. L.M. Luttrell, Y. Daaka, R.J. Lefkowitz, Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177-183 (1999) (Pubitemid 29164031)
9. F.S. Lee, M.V. Chao, Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA 98(6), 3555-3560 (2001) (Pubitemid 32220883)
10. K.L. Pierce, L.M. Luttrell, R.J. Lefkowitz, New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20(13), 1532-1539 (2001) (Pubitemid 32336840)
11. P.O. Hackel, E. Zwick, N. Prenzel, A. Ullrich, Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11(2), 184-189 (1999) (Pubitemid 29164032)
12. B. Hellman, A. Lernmark, Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology 84(6), 1484-1488 (1969)
13. L. Krulich, A.P. Dhariwal, S.M. McCann, Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83(4), 783-790 (1968)
14. Y.C. Patel, S. Reichlin, Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology 102(2), 523-530 (1978) (Pubitemid 8308361)
15. Y.C. Patel, Somatostatin and its receptor family. Front. Neuroendocrinol. 20(3), 157-198 (1999) (Pubitemid 29362641)
16. J. Epelbaum, P. Dournaud, M. Fodor, C. Viollet, The neurobiology of somatostatin. Crit. Rev. Neurobiol. 8(1-2), 25-44 (1994) (Pubitemid 24024904)
17. Y.C. Patel, Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20(6), 348-367 (1997) (Pubitemid 27410043)
18. U. Kumar, D. Laird, C.B. Srikant, E. Escher, Y.C. Patel, Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138(10), 4473-4476 (1997) (Pubitemid 27408496)
19. K.V. Sorensen, S.E. Christensen, A.P. Hansen, E. Pedersen, H. Orskov, Cerebrospinal fluid somatostatin inversely correlated with disease activity in multiple sclerosis. Lancet 1(8331), 988 (1983)
20. D. Hoyer, H. Lubbert, C. Bruns, Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 350(5), 441-453 (1994) (Pubitemid 24345234)
21. A. Schonbrunn, H. Tashjian Jr., Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J. Biol. Chem. 253(18), 6473-6483 (1978) (Pubitemid 9025329)
22. K.D. Pfleger, K.A. Eidne, Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem. J. 385(Pt 3), 625-637 (2005) (Pubitemid 40208822)
23. S. Bulenger, S. Marullo, M. Bouvier, Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26(3), 131-137 (2005) (Pubitemid 40313592)
24. M. Duran-Prado, M.M. Malagon, F. Gracia-Navarro, J.P. Castano, Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol. Cell. Endocrinol. 286(1-2), 63-68 (2008)
25. J.M. Gripentrog, K.P. Kantele, A.J. Jesaitis, H.M. Miettinen, Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor. J. Immunol. 171(6), 3187-3193 (2003) (Pubitemid 37093544)
26. B.H. Meyer, J.M. Segura, K.L. Martinez, R. Hovius, N. George, K. Johnsson, H. Vogel, FRET imaging reveals that functional neurokinin-1 receptors are monomeric and reside in membrane microdomains of live cells. Proc. Natl. Acad. Sci. USA 103(7), 2138-2143 (2006) (Pubitemid 43271636)
27. M. Grant, B. Collier, U. Kumar, Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J. Biol. Chem. 279(35), 36179-36183 (2004) (Pubitemid 39128952)
28. M. Pfeiffer, T. Koch, H. Schroder, M. Klutzny, S. Kirscht, H.J. Kreienkamp, V. Hollt, S. Schulz, Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276(17), 14027-14036 (2001)
29. M.A. Ayoub, C. Couturier, E. Lucas-Meunier, S. Angers, P. Fossier, M. Bouvier, R. Jockers, Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem. 277(24), 21522-21528 (2002) (Pubitemid 34952296)
30. M. Rocheville, D.C. Lange, U. Kumar, R. Sasi, R.C. Patel, Y.C. Patel, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275(11), 7862-7869 (2000) (Pubitemid 30159693)
31. M. Grant, R.C. Patel, U. Kumar, The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J. Biol. Chem. 279(37), 38636-38643 (2004) (Pubitemid 39296019)
32. M. Duran-Prado, C. Bucharles, B.J. Gonzalez, R. Vazquez-Martinez, A.J. Martinez-Fuentes, S. Garcia-Navarro, S.J. Rhodes, H. Vaudry, M.M. Malagon, J.P. Castano, Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 148(1), 411-421 (2007) (Pubitemid 46021473)
33. S.A. War, R.K. Somvanshi, U. Kumar, Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim. Biophys. Acta 1813(3), 390-402 (2011)
34. R.K. Somvanshi, S. Billova, G. Kharmate, P.S. Rajput, U. Kumar, C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell. Signal. 21(9), 1396-1414 (2009)
35. A. Baragli, H. Alturaihi, H.L. Watt, A. Abdallah, U. Kumar, Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19(11), 2304-2316 (2007) (Pubitemid 47361686)
36. M. Grant, H. Alturaihi, P. Jaquet, B. Collier, U. Kumar, Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22(10), 2278-2292 (2008)
37. M. Pfeiffer, T. Koch, H. Schroder, M. Laugsch, V. Hollt, S. Schulz, Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 277(22), 19762-19772 (2002) (Pubitemid 34967492)
38. M. Rocheville, D.C. Lange, U. Kumar, S.C. Patel, R.C. Patel, Y.C. Patel, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288(5463), 154-157 (2000) (Pubitemid 30203051)
39. R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Heterodimerization of beta2 adrenergic receptor and somatostatin receptor 5: implications in modulation of signaling pathway. J. Mol. Signal. 6, 9 (2011)
40. R.K. Somvanshi, S.A. War, N. Chaudhari, X. Qiu, U. Kumar, Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta1-adrenergic receptor and somatostatin receptor-5. Cell. Signal. 23(5), 794-811 (2011)
41. G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 152(3), 931-945 (2011)
42. G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim. Biophys. Acta 1813(6), 1172-1189 (2011)
43. H.L. Watt, G.D. Kharmate, U. Kumar, Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell. Signal. 21(3), 428-439 (2009)
44. M. Grant, U. Kumar, The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul. Pept. 159(1-3), 3-8 (2010)
45. R.C. Patel, U. Kumar, D.C. Lamb, J.S. Eid, M. Rocheville, M. Grant, A. Rani, T. Hazlett, S.C. Patel, E. Gratton, Y.C. Patel, Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. USA 99(5), 3294-3299 (2002) (Pubitemid 34240625)
46. Y.C. Patel, M.T. Greenwood, A. Warszynska, R. Panetta, C.B. Srikant, All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase. Biochem. Biophys. Res. Commun. 198(2), 605-612 (1994) (Pubitemid 24178411)
47. M.A. Olayioye, R.M. Neve, H. Lane, N.E. Hynes, The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000) (Pubitemid 30428195)
48. D.C. Lev, L.S. Kim, V. Melnikova, M. Ruiz, H.N. Ananthaswamy, J.E. Price, Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br. J. Cancer 91(4), 795-802 (2004) (Pubitemid 39141643)
49. S. Okubo, J. Kurebayashi, T. Otsuki, Y. Yamamoto, K. Tanaka, H. Sonoo, Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells. Br. J. Cancer 90(1), 236-244 (2004) (Pubitemid 38174967)
50. A. deFazio, Y.E. Chiew, R.L. Sini, P.W. Janes, R.L. Sutherland, Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 87(4), 487-498 (2000) (Pubitemid 30639806)
51. D.F. Stern, ErbBs in mammary development. Exp. Cell Res. 284(1), 89-98 (2003) (Pubitemid 36331968)
52. H.K. Gan, M. Lappas, D.X. Cao, A. Cvrljevdic, A.M. Scott, T.G. Johns, Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J. Cell Mol. Med. 13(9B), 3993-4001 (2009)
53. D. Gerber, N. Sal-Man, Y. Shai, Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J. Biol. Chem. 279(20), 21177-21182 (2004) (Pubitemid 38656521)
54. A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, S. Yokoyama, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12(3), 541-552 (2003) (Pubitemid 37222478)
55. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, M. Kofler, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11(2), 495-505 (2003) (Pubitemid 36293841)
56. L.N. Klapper, M.H. Kirschbaum, M. Sela, Y. Yarden, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25-79 (2000) (Pubitemid 29439302)
57. K.L. Carraway 3rd, L.C. Cantley, A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78(1), 5-8 (1994)
58. J.L. Gilmore, D.J. Riese 2nd, secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol. Res. 14(11-12), 589-602 (2004) (Pubitemid 40178960)
59. K.L. Carraway 3rd, S.P. Soltoff, A.J. Diamonti, L.C. Cantley, Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270(13), 7111-7116 (1995)
60. B.D. Cohen, P.A. Kiener, J.M. Green, L. Foy, H.P. Fell, K. Zhang, The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271(48), 30897-30903 (1996) (Pubitemid 26404114)
61. P.M. Guy, J.V. Platko, L.C. Cantley, R.A. Cerione, K.L. Carraway 3rd, Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91(17), 8132-8136 (1994)
62. T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas 3rd, N.E. Hynes, The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100(15), 8933-8938 (2003) (Pubitemid 36899201)
63. R. Pinkas-Kramarski, M. Shelly, S. Glathe, B.J. Ratzkin, Y. Yarden, Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271(32), 19029-19032 (1996) (Pubitemid 26271558)
64. K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason, S.K. Yoshinaga, Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271(7), 3884-3890 (1996) (Pubitemid 26065710)
65. J. Baulida, G. Carpenter, Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp. Cell Res. 232(1), 167-172 (1997) (Pubitemid 27172231)
66. Z. Wang, L. Zhang, T.K. Yeung, X. Chen, Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol. Biol. Cell 10(5), 1621-1636 (1999) (Pubitemid 29230913)
67. H. Waterman, I. Sabanai, B. Geiger, Y. Yarden, Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. 273(22), 13819-13827 (1998) (Pubitemid 28268432)
68. A.E. Lenferink, R. Pinkas-Kramarski, M.L. van de Poll, M.J. van Vugt, L.N. Klapper, E. Tzahar, H. Waterman, M. Sela, E.J. van Zoelen, Y. Yarden, Differential endocytic routing of homoand hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17(12), 3385-3397 (1998) (Pubitemid 28279512)
69. R. Zandi, A.B. Larsen, P. Andersen, M.T. Stockhausen, H.S. Poulsen, Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19(10), 2013-2023 (2007) (Pubitemid 47353811)
70. E. Peles, R. Ben-Levy, E. Tzahar, N. Liu, D. Wen, Y. Yarden, Cell-type specific interaction of Neu differentiation factor (NDF/ heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12(3), 961-971 (1993) (Pubitemid 23095845)
71. G.D. Plowman, J.M. Green, J.M. Culouscou, G.W. Carlton, V.M. Rothwell, S. Buckley, Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366(6454), 473-475 (1993) (Pubitemid 24013882)
72. M.X. Sliwkowski, G. Schaefer, R.W. Akita, J.A. Lofgren, V.D. Fitzpatrick, A. Nuijens, B.M. Fendly, R.A. Cerione, R.L. Vandlen, K.L. Carraway 3rd, Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269(20), 14661-14665 (1994)
73. X. Qian, C.M. LeVea, J.K. Freeman, W.C. Dougall, M.I. Greene, Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91(4), 1500-1504 (1994) (Pubitemid 24059040)
74. S. Gavi, D. Yin, E. Shumay, H.Y. Wang, C.C. Malbon, Insulinlike growth factor-I provokes functional antagonism and internalization of beta1-adrenergic receptors. Endocrinology 148(6), 2653-2662 (2007) (Pubitemid 46984795)
75. F.S. Lee, Novel crosstalk between G protein-coupled receptors and NMDA receptors. Exp. Neurol. 183(2), 269-272 (2003) (Pubitemid 37205069)
76. J.A. Garcia-Sainz, M.T. Romero-Avila, C. Medina Ldel, Dissecting how receptor tyrosine kinases modulate G protein-coupled receptor function. Eur. J. Pharmacol. 648(1-3), 1-5 (2010)
77. U. Kumar, S.I. Grigorakis, H.L. Watt, R. Sasi, L. Snell, P. Watson, S. Chaudhari, Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 92(2), 175-186 (2005) (Pubitemid 40933583)
78. H.L. Watt, U. Kumar, Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell. Int. 6, 5 (2006)
79. J. Held-Feindt, F. Forstreuter, T. Pufe, R. Mentlein, Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res. Mol. Brain Res. 87(1), 12-21 (2001) (Pubitemid 32167036)
80. M.T. Lee, C. Liebow, A.R. Kamer, A.V. Schally, Effects of epidermal growth factor and analogues of luteinizing hormonereleasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc. Natl. Acad. Sci. USA 88(5), 1656-1660 (1991) (Pubitemid 21916284)
81. S. Hart, O.M. Fischer, N. Prenzel, E. Zwick-Wallasch, M. Schneider, L. Hennighausen, A. Ullrich, GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 386(9), 845-855 (2005) (Pubitemid 41448140)
82. E.J. Filardo, J.A. Quinn, K.I. Bland, A.R. Frackelton Jr., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14(10), 1649-1660 (2000)
83. N. Prenzel, E. Zwick, H. Daub, M. Leserer, R. Abraham, C. Wallasch, A. Ullrich, EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402(6764), 884-888 (1999)
84. H. Daub, F.U. Weiss, C. Wallash, A. Ullrich, Role of transactivation of the EGF receptor in signalling by G-protein coupled receptors. Nature 379, 557-560 (1996) (Pubitemid 26049585)
85. D. Darmoul, V. Gratio, H. Devaud, M. Laburthe, Proteaseactivated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J. Biol. Chem. 279(20), 20927-20934 (2004) (Pubitemid 38656491)
86. H. Shankaran, H.S. Wiley, H. Resat, Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys. J. 90(11), 3993-4009 (2006) (Pubitemid 43846116)
87. N.E. Willmarth, A. Baillo, M.L. Dziubinski, K. Wilson, D.J. Riese Ii, S.P. Ethier, Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell. Signal. 21(2), 212-219 (2009)
88. N. Moghal, P.W. Sternberg, Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11(2), 190-196 (1999) (Pubitemid 29164033)
89. W.J. Wu, S. Tu, R.A. Cerione, Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 114(6), 715-725 (2003) (Pubitemid 37186766)
90. T. Fukazawa, S. Miyake, V. Band, H. Band, Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 271(24), 14554-14559 (1996) (Pubitemid 26190360)
91. T. Florio, S. Thellung, S. Arena, A. Corsaro, A. Bajetto, G. Schettini, P.J. Stork, Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J. Physiol. Paris 94(3-4), 239-250 (2000)
92. T. Florio, H. Yao, K.D. Carey, T.J. Dillon, P.J. Stork, Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13(1), 24-37 (1999) (Pubitemid 29022277)
93. H. Lahlou, N. Saint-Laurent, J.P. Esteve, A. Eychene, L. Pradayrol, S. Pyronnet, C. Susini, sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Rafdependent ERK2 activation. J. Biol. Chem. 278(41), 39356-39371 (2003) (Pubitemid 37248491)
94. A. Esparis-Ogando, E. Diaz-Rodriguez, J.C. Montero, L. Yuste, P. Crespo, A. Pandiella, Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol. Cell. Biol. 22(1), 270-285 (2002) (Pubitemid 33144274)
95. J.C. Montero, A. Ocana, M. Abad, M.J. Ortiz-Ruiz, A. Pandiella, A. Esparis-Ogando, Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4(5), e5565 (2009)
96. N.E. Hynes, J.H. Dey, PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 15(5), 353-355 (2009)
97. B.N. Rexer, R. Ghosh, C.L. Arteaga, Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin. Cancer Res. 15(14), 4518-4520 (2009)
98. B.N. Rexer, J.A. Engelman, C.L. Arteaga, Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8(1), 18-22 (2009)
99. K. Berns, H.M. Horlings, B.T. Hennessy, M. Madiredjo, E.M. Hijmans, K. Beelen, S.C. Linn, A.M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, R.L. Beijersbergen, G.B. Mills, M.J. van de Vijver, R. Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395-402 (2007) (Pubitemid 47539306)
100. C.B. Srikant, S.H. Shen, Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 137(8), 3461-3468 (1996) (Pubitemid 26250200)
101. C. Susini, L. Buscail, Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17(12), 1733-1742 (2006) (Pubitemid 44884046)
102. M.P. Sanderson, P.J. Dempsey, A.J. Dunbar, Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24(2), 121-136 (2006)